CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Cincinnati, Ohio, United States and 43 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
Kettering, Ohio, United States and 33 other locations
the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung...
Phase 1, Phase 2
Cincinnati, Ohio, United States and 8 other locations
The main aim of this study is to:* evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\]...
Phase 2
Cincinnati, Ohio, United States of America and 79 other locations
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Su ...
Phase 2
Cincinnati, Ohio, United States and 70 other locations
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T Syst ...
Phase 2
Edgewood, Kentucky, United States and 23 other locations
survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer...
Phase 2
Cincinnati, Ohio, United States and 38 other locations
NSCLC comprises of approximately 84 percent (%) of all lung cancers and is often diagnosed at advanced stage due to poor prognosis....
Phase 2
Cincinnati, Ohio, United States and 57 other locations
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer ...
Phase 2
Cincinnati, Ohio, United States and 24 other locations
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS...
Phase 3
Cincinnati, Ohio, United States of America and 70 other locations
Clinical trials
Research sites
Resources
Legal